Compliance, Regulatory Requirements
17 Jan 2025
regulations, pharmaceuticals, fda, comment period, accelerated approval, biologics
📄FDA Extends Comment Period for Accelerated Approval Guidance
The Food and Drug Administration (FDA or the Agency) is extending the comment period for the draft guidance for industry entitled "Expedited Program for Serious Conditions--Accelerated Approval of Drugs and Biologics" that appeared in the Federal Register of December 6, 2024. In the notice of availability for the draft guidance, FDA requested comments on the draft guidance. The Agency is taking this action in response to requests for an extension to allow interested persons additional time to submit comments.
Learn More